BRIEF Bendamustine and Rituximab In Elderly Follicular
The objective of this study is to evaluate the complete response rate after a short induction treatment with rituximab (375mg/m2)and bendamustine (90mg/m2)in In Elderly (≥ 60 years old) patients with untreated Follicular lymphoma, with an intermediate or high FLIPI score and without high tumor burden.

This short induction is followed by a rituximab (375mg/m2)maintenance/ Induction schedule:Rituximab+Bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, rituximab on day 22, Bendamustine on Day 29, Bendamustine on Day 30 Maintenance schedule: 12 infusions of rituximab, each 8 weeks
Follicular Lymphoma
DRUG: Rituximab + bendamustine
Complete response rate according to Cheson criteria 1999 after a short induction treatment by rituximab and bendamustine, 12 weeks
Complete response rate according to Cheson criteria 1999 after 24 months of maintenance therapy with Rituximab, 26 months|Partial and objective response rates at the end of induction phase, 12 weeks|Duration of response, From the time of attainment of CR or PR to the date of first documented disease progression, relapse or death from any cause|Progression free survival, From the date of randomization to the date of first documented disease progression, relapse, initiation of new anti-lymphoma therapy or death from any cause.|Overall survival, From the date of randomization to the date of death from any cause|Time before retreatment, From the end of primary treatment until the institution of the next therapy|Immediate toxicity, 12 weeks|Long term toxicity, Until death of the patients|Evaluation of QoL, 7 years
The objective of this study is to evaluate the complete response rate after a short induction treatment with rituximab (375mg/m2)and bendamustine (90mg/m2)in In Elderly (≥ 60 years old) patients with untreated Follicular lymphoma, with an intermediate or high FLIPI score and without high tumor burden.

This short induction is followed by a rituximab (375mg/m2)maintenance/ Induction schedule:Rituximab+Bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, rituximab on day 22, Bendamustine on Day 29, Bendamustine on Day 30 Maintenance schedule: 12 infusions of rituximab, each 8 weeks